Recombinant Von Willebrand Factor in Subjects With Severe Von Willebrand Disease Undergoing Surgery


The purpose of the study is to assess the efficacy and safety of recombinant von Willebrand factor (rVWF) with or without ADVATE in major and minor elective surgical procedures in adult patients with hereditary severe von Willebrand disease (VWD).

Study Start Date

April 2015

Estimated Completion Date

July 2016


  • Biological: Recombinant von Willebrand Factor (rVWF)


  • Internal Medicine: Hematology/Oncology
  • Oncology: Coagulation/Bleeding Dz
  • Physician Assistant: Hematology/Oncology

MeSH Terms

  • Von Willebrand Diseases

Study ID

Baxter Healthcare Corporation -- 071101



Trial ID


Study Type


Trial Phase

Phase 3

Enrollment Quota



Baxter Healthcare Corporation

Inclusion Criteria

  • Diagnosis of severe von Willebrand disease (VWD) as listed below and elective surgical procedure planned 1. Type 1 (Von Willebrand factor : Ristocetin cofactor activity (VWF:RCo) <20 IU/dL), or 2. Type 2A (as verified by multimer pattern), Type 2B (as diagnosed by genotype), Type 2N (FVIII:C<10% and historically documented genetics), Type 2M, or 3. Type 3 (Von Willebrand factor antigen (VWF:Ag) ? 3 IU/dL)
  • VWD with a history of requiring substitution therapy with von Willebrand factor (VWF) concentrate to control bleeding
  • If type 3 VWD (VWF Antigen /VWF:Ag ? 3 IU/dL), participant has a medical history of at least 20 exposure days to VWF/FVIII coagulation factor concentrates (including cryoprecipitate or fresh frozen plasma)
  • If type 1 or type 2 VWD, participant has a medical history of 5 exposure days or a past major surgery requiring VWF/FVIII coagulation factor concentrates (including cryoprecipitate or fresh frozen plasma)
  • Participant is at least 18 years of age
  • If female of childbearing potential, participant presents with a negative pregnancy test
  • If applicable, participant agrees to employ adequate birth control measures for the duration of the study
  • Participant is willing and able to comply with the requirements of the protocol

Exclusion Criteria

  • Diagnosis of pseudo VWD or another hereditary or acquired coagulation disorder (eg, qualitative and quantitative platelet disorders or elevated prothrombin time [PT] / international normalized ratio [INR] > 1.4)
  • History or presence of a VWF inhibitor at screening
  • History or presence of a factor VIII (FVIII) inhibitor with a titer ? 0.4 BU (Nijmegen-modified Bethesda assay ) or ? 0.6 BU (by Bethesda assay)
  • Known hypersensitivity to any of the components of the study drugs, such as to mouse or hamster proteins
  • Medical history of immunological disorders, excluding seasonal allergic rhinitis/conjunctivitis, mild asthma, food allergies or animal allergies
  • Medical history of a thromboembolic event
  • HIV positive with an absolute CD4 count < 200/mm3
  • Platelet count < 100,000/mL
  • Diagnosis of significant liver disease, as evidenced by, but not limited to, any of the following: serum alanine aminotransferase (ALT) 5 times the upper limit of normal
  • hypoalbuminemia portal vein hypertension (eg. presence of otherwise unexplained splenomegaly, history of esophageal varices) or liver cirrhosis classified as Child B or C
  • Diagnosis of renal disease, with a serum creatinine level ? 2 .5mg/dL
  • Participant has been treated with an immunomodulatory drug, excluding topical treatment (eg, ointments, nasal sprays), within 30 days prior to signing the informed consent
  • Participant is pregnant or lactating at the time informed content is obtained
  • Participant has participated in another clinical study involving an investigational product (IP), other than rVWF with or without ADVATE, or investigational device within 30 days prior to enrollment or is scheduled to participate in another clinical study involving an IP or investigational device during the course of this study. However, eligible patients participating in the rVWF Prophylaxis Study (071301) may be enrolled.
  • Progressive fatal disease and/or life expectancy of less than 3 months
  • Participant is identified by the investigator as being unable or unwilling to cooperate with study procedures
  • Participant suffers from a mental condition rendering him/her unable to understand the nature, scope and possible consequences of the study and/or evidence of an uncooperative attitude
  • Participant is in prison or compulsory detention by regulatory and/or juridical order
  • Participant is a member of the study team conducting this study or in a dependent relationship with one of the study team members. Dependent relationships include close relatives (ie, children, partner/spouse, siblings, parents) as well as employees.




18 Years and older

Accepts Healthy Volunteers


Study Locations and Contact Information (12)

Study Location Distance Name Phone Email
Dana Farber Cancer Institute - Boston, Massachusetts 2.4 miles None None None
Rutgers Robert Wood Johnson Medical School - New Brunswick, New Jersey 217.0 miles None None None
John Hopkins University - Baltimore, Maryland 356.4 miles None None None
Case Western Reserve University Hospital - Cleveland, Ohio 544.0 miles None None None
Cleveland Clinic - Cleveland, Ohio 544.9 miles None None None
Duke University Medical Center - Durham, North Carolina 608.4 miles None None None
Medical University of South Carolina MUSC - Charleston, South Carolina 821.2 miles None None None
Georgia Regents University - Augusta, Georgia 855.1 miles None None None
Blood Center of South East Wisconsin - Milwaukee, Wisconsin 856.6 miles None None None
University of Miami Jackson Memorial Hospital - Miami, Florida 1,259.8 miles None None None
University of Oklahoma Health Sciences Center - Oklahoma City, Oklahoma 1,493.6 miles None None None
University of Colorado Hemophilia Thrombosis Center - Aurora, Colorado 1,759.8 miles None None None provides clinical trial listings in an easy to view format. All clinical trial information is pulled directly from This website does not guarantee acceptance into any clinical trial, and is not responsible for adverse events that may be incurred from a clinical trial.